Trial · NCT03154827
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
NCT03154827, Phase 1, Phase 2, Terminated, BioLineRx, Ltd.; results first posted 2024-09-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML). Trials, record NCT03154827. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03154827
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
- NCT number
- NCT03154827
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- BioLineRx, Ltd.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- BL-8040, Atezolizumab
- First posted
- 2017-05-16
- Last updated
- 2024-09-05
- Results first posted
- 2024-09-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relapse Free Survival | Up to 5 years | Relapse Free Survival measured from the time of Complete Remission to the relapse or death from any cause whichever comes first |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Relapse Free Survival | Up to 5 years | All eligible patients who received at least 1 dose of study medications |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Combination Treatment Single Arm | 1 | |
| Overall Study | COMPLETED | Combination Treatment Single Arm | 0 | |
| Overall Study | NOT COMPLETED | Combination Treatment Single Arm | 1 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 2 |
| other | Vomiting | Gastrointestinal disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Nausea | Gastrointestinal disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Rhinitis | Respiratory, thoracic and mediastinal disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Decreased appetite | Metabolism and nutrition disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Dermatitis allergic | Skin and subcutaneous tissue disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Anxiety | Psychiatric disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Constipation | Gastrointestinal disorders | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
| other | Bronchitis | Infections and infestations | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Combination Treatment of BL-8040 With Atezolizumab | 0 | 1 |
| Total, other adverse events | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 |
| Total, serious adverse events | Combination Treatment of BL-8040 With Atezolizumab | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03154827
GET https://conductscience.org/api/trials/v1/NCT03154827/registered